Related Experiment Video

Updated: Mar 26, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized

Vincent Leroy1, Peter Angus2, Jean-Pierre Bronowicki3

  • 1Clinique Universitaire d'Hepato-Gastroentérologie, Pôle Digidune, CHU de Grenoble and Unité INSERM/Université Grenoble Alpes U823, IAPC Institut Albert Bonniot, Grenoble, France.

Hepatology (Baltimore, Md.)
|January 30, 2016
PubMed

Insights

Hepatitis C genotype 3 patients with advanced liver disease achieved high sustained virological response (SVR12) using daclatasvir-sofosbuvir-ribavirin. Treatment duration of 12 or 16 weeks showed similar efficacy and good tolerability.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) genotype 3 infection with advanced liver disease requires effective therapies.
  • Previous studies showed high efficacy of daclatasvir (DCV) and sofosbuvir (SOF) in noncirrhotic patients.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of DCV-SOF plus ribavirin (RBV) in patients with HCV genotype 3 and advanced liver disease.
  • To compare the outcomes of 12-week versus 16-week treatment durations.

Main Methods:

  • Phase III ALLY-3+ study enrolled 50 treatment-naïve or experienced patients with advanced fibrosis or compensated cirrhosis.
  • Patients received open-label DCV-SOF with weight-based RBV for 12 or 16 weeks.
  • Primary endpoint was sustained virological response at post-treatment week 12 (SVR12).

Main Results:

  • Overall SVR12 was 90% (45/50), with 88% for the 12-week group and 92% for the 16-week group.
  • All patients with advanced fibrosis achieved SVR12.
  • SVR12 in patients with cirrhosis was 86% overall, with high rates in both treatment durations and across treatment experience groups.

Conclusions:

  • The combination of DCV-SOF-RBV demonstrated high efficacy and was well tolerated in genotype 3 HCV patients with advanced liver disease.
  • Both 12 and 16 weeks of treatment resulted in similar high SVR12 rates.
  • Treatment outcomes were consistent regardless of prior treatment experience.
Abstract

More Related Videos

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

13.9K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
34
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
414
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.6K
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
207
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
475